elotuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5072 915296-00-3

Description:

MoleculeDescription

Synonyms:

  • elotuzumab
  • empliciti
  • BMS-901608
  • HuLuc63
a humanized monoclonal antibody that selectively targets glycoproteins expressed on myeloma cells
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
50 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Sept. 28, 2016 PMDA Bristol-Myers Squibb
May 11, 2016 EMA Bristol-Myers Squibb
Nov. 30, 2015 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 219.81 24.78 98 3329 106772 90518248
Plasma cell myeloma 214.68 24.78 74 3353 40754 90584266
Neutropenia 74.13 24.78 64 3363 224840 90400180
Platelet count decreased 68.84 24.78 50 3377 136919 90488101
Pneumonia 61.47 24.78 96 3331 637963 89987057
Cytomegalovirus infection 53.22 24.78 24 3403 26578 90598442
Paraproteinaemia 52.50 24.78 9 3418 248 90624772
Death 51.44 24.78 74 3353 456477 90168543
Plasma cell myeloma recurrent 48.80 24.78 14 3413 4214 90620806
Thrombocytopenia 48.61 24.78 49 3378 208676 90416344
Anaemia 48.50 24.78 63 3364 352739 90272281
Lymphocyte count decreased 46.91 24.78 24 3403 35026 90589994
Pyrexia 45.86 24.78 86 3341 660399 89964621
Neutrophil count decreased 45.00 24.78 30 3397 71502 90553518
Febrile infection 43.50 24.78 11 3416 2058 90622962
Pneumococcal sepsis 41.07 24.78 9 3418 909 90624111
Pneumonia pneumococcal 35.95 24.78 10 3417 2692 90622328
Diarrhoea 33.52 24.78 94 3333 939096 89685924
Neuropathy peripheral 31.56 24.78 32 3395 136938 90488082
Febrile neutropenia 29.42 24.78 33 3394 158316 90466704
Toxic shock syndrome 29.29 24.78 7 3420 1037 90623983
Cytomegalovirus infection reactivation 29.12 24.78 11 3416 7789 90617231
Sepsis 27.63 24.78 34 3393 179780 90445240
Beta haemolytic streptococcal infection 27.55 24.78 8 3419 2511 90622509

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 140.41 25.10 104 4278 108296 42508657
Plasma cell myeloma 124.33 25.10 71 4311 47507 42569446
Pneumonia 108.77 25.10 171 4211 421978 42194975
Neutropenia 64.19 25.10 90 4292 199341 42417612
Febrile infection 40.83 25.10 14 4368 2757 42614196
Platelet count decreased 40.75 25.10 60 4322 138521 42478432
Keratopathy 39.45 25.10 10 4372 688 42616265
Squamous cell carcinoma of skin 38.64 25.10 21 4361 12705 42604248
Neuropathy peripheral 35.71 25.10 48 4334 101805 42515148
Cytomegalovirus infection reactivation 35.49 25.10 19 4363 11159 42605794
Campylobacter gastroenteritis 35.08 25.10 10 4372 1075 42615878
Plasma cell myeloma refractory 32.50 25.10 10 4372 1400 42615553
Plasma cell myeloma recurrent 30.90 25.10 14 4368 5743 42611210
Sepsis 30.75 25.10 65 4317 199269 42417684
Factor VII deficiency 30.52 25.10 5 4377 35 42616918
Pyrexia 30.37 25.10 99 4283 393943 42223010
Anaemia 29.78 25.10 79 4303 280199 42336754
Pneumonia mycoplasmal 28.91 25.10 8 4374 772 42616181
White blood cell count decreased 28.47 25.10 45 4337 110351 42506602
Pneumonia respiratory syncytial viral 28.16 25.10 9 4373 1425 42615528
Respirovirus test positive 27.25 25.10 5 4377 72 42616881
Visceral leishmaniasis 25.81 25.10 8 4374 1146 42615807

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 320.42 25.25 173 6635 174394 110408097
Plasma cell myeloma 262.78 25.25 110 6698 62826 110519665
Pneumonia 161.18 25.25 231 6577 876483 109706008
Neutropenia 140.22 25.25 142 6666 374478 110208013
Platelet count decreased 108.06 25.25 99 6709 230344 110352147
Plasma cell myeloma recurrent 89.19 25.25 28 6780 7014 110575477
Anaemia 88.28 25.25 136 6672 546950 110035541
Pyrexia 77.20 25.25 170 6638 898095 109684396
Thrombocytopenia 75.75 25.25 100 6708 348785 110233706
Neutrophil count decreased 70.77 25.25 59 6749 120882 110461609
Cytomegalovirus infection reactivation 69.60 25.25 30 6778 18303 110564188
Sepsis 62.21 25.25 88 6720 327258 110255233
Plasma cell myeloma refractory 57.17 25.25 15 6793 1986 110580505
White blood cell count decreased 54.81 25.25 69 6739 229321 110353170
Lymphocyte count decreased 53.61 25.25 37 6771 57206 110525285
Febrile infection 53.48 25.25 17 6791 4431 110578060
Death 50.77 25.25 124 6684 698745 109883746
Cytomegalovirus infection 50.53 25.25 35 6773 54409 110528082
Paraproteinaemia 47.09 25.25 10 6798 531 110581960
Neuropathy peripheral 46.14 25.25 56 6752 179221 110403270
Septic shock 43.48 25.25 51 6757 157477 110425014
Febrile neutropenia 43.07 25.25 73 6735 316694 110265797
Keratopathy 42.65 25.25 11 6797 1362 110581129
Atrial fibrillation 38.15 25.25 58 6750 229584 110352907
Plasma cell leukaemia 38.08 25.25 11 6797 2077 110580414
Squamous cell carcinoma of skin 36.94 25.25 19 6789 17184 110565307
Campylobacter gastroenteritis 34.46 25.25 10 6798 1919 110580572
COVID-19 33.98 25.25 57 6751 245003 110337488
Cytokine release syndrome 32.46 25.25 30 6778 70276 110512215
Pancytopenia 32.10 25.25 51 6757 209562 110372929
Pneumocystis jirovecii pneumonia 31.72 25.25 24 6784 42711 110539780
Deep vein thrombosis 28.59 25.25 39 6769 139848 110442643
Factor VII deficiency 28.12 25.25 5 6803 103 110582388
COVID-19 pneumonia 27.88 25.25 21 6787 37122 110545369
Bacteraemia 27.54 25.25 22 6786 42368 110540123
Acute myeloid leukaemia 27.40 25.25 21 6787 38089 110544402
Pulmonary embolism 27.25 25.25 48 6760 214426 110368065
Respirovirus test positive 27.05 25.25 5 6803 129 110582362
Listeriosis 26.73 25.25 9 6799 2805 110579686
Basal cell carcinoma 26.27 25.25 22 6786 45248 110537243
Human metapneumovirus test 26.09 25.25 3 6805 0 110582491

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
FDA CS M0001357 Antibodies, Monoclonal
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000192337 SLAMF7-directed Antibody Interactions
FDA EPC N0000192338 SLAMF7-directed Immunostimulatory Antibody
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamabipilimumab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple myeloma indication 109989006 DOID:9538
Relapse multiple myeloma indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
SLAM family member 7 Membrane receptor ANTIBODY BINDING Kd 8.05 IUPHAR DRUG LABEL

External reference:

IDSource
1351PE5UGS UNII
4035187 VANDF
C1832049 UMLSCUI
CHEBI:750089 CHEBI
CHEMBL1743010 ChEMBL_ID
DB06317 DRUGBANK_ID
9074 INN_ID
C546027 MESH_SUPPLEMENTAL_RECORD_UI
8361 IUPHAR_LIGAND_ID
1726104 RXNORM
237251 MMSL
31305 MMSL
d08403 MMSL
016608 NDDF
715660001 SNOMEDCT_US
781350003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-2291 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 mg INTRAVENOUS BLA 25 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-4522 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 400 mg INTRAVENOUS BLA 25 sections